Molecular mechanisms of lipid disorders in nephrotic syndrome

Kidney International

Volumn 63, Issue 5, 2003, Pages 1964-1976

  Vaziri, Nosratola D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ACAT; Cholesterol; HDL; Hepatic lipase; HMG CoA reductase; Hyperlipidemia; LCAT; LDL; Lipoprotein lipase; Proteinuria; SR B1; VLDL

Indexed keywords

CHOLESTEROL; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL FEATURE; FATTY ACID TRANSPORT; FEMALE; HUMAN; HYPERTENSION; LEG EDEMA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL;

EID: 0037406342     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00941.x     Document Type: Article

References (76)

1. JOVEN J, VILLABONA C, VILELLA E, et al: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579-584, 1990
2. WHEELER DC, BERNARD DB: Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 23:331-346, 1994
3. APPEL G: Lipid abnormalities in renal disease. Kidney Int 39:169-183, 1991
4. RADHAKRISHNAN J, APPEL AS, VALERI A, et al: The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 22:135-142, 1993
5. STENVINKEL P, BERGLUND L, HEIMBURGER O, et al: Lipoprotein(a) in nephrotic syndrome. Kidney Int 44:1116-11123, 1993
6. GHERARDI E, ROTA E, CALANDRA S, et al: Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur J Clin Invest 7:563-570, 1977
7. DE SAIN-VAN DER VELDEN MG, KAYSEN GA, BARRETT HA, et al: Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53:994-1001, 1998
8. LEVY E, ZIV E, BAR-ON H, SHAFRIR E: Experimental nephrotic syndrome: Removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin. Biochim Biophys Acta 1043:259-266, 1990
9. GARBER DW, GOTTLIEB BA, MARSH JB, et al: Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 74:1375-1383, 1984
10. WARWICK GL, PACKARD CJ, DEMANT T, et al: Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 40:129-138, 1991
11. KAYSEN GA, MEHENDRU L, PAN XM, et al: Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis. Am J Physiol 263:F335-341, 1992
12. WARWICK GL, CASLAKE MJ, BOULTON-JONES JM, et al: Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 39:187-192, 1990
13. COOPER AD: Hepatic lipoprotein and cholesterol metabolism, in Hepatology, edited by ZAKIM D, BOYER T, Philadelphia, Saunders, 1989, pp 105-137
14. NESS GC, CHAMBERS CM: Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: The concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 224:8-19, 2000
15. VAZIRI ND, LIANG KH: Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48:1979-1985, 1995
16. VAZIRI ND, SATO T, LIANG K: Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int 63:1756-1763, 2003
17. HORTON JD, CUTHBERT JA, SPADY DK: Regulation of hepatic 7 alpha-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem 270:5381-5387, 1995
18. LIANG KH, OVEISI F, VAZIRI ND: Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 49:855-860, 1996
19. PAHL MV, OVEISI F, KHAMISEH G, et al: Intestinal absorption and biliary secretion of cholesterol in rats with nephrotic syndrome. Nephrol Dial Transplant 13:1446-1451, 1998
20. VAZIRI ND, LIANG K: Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50:887-893, 1996
21. VAZIRI ND, LIANG KH: Upregulation of Acyl-Coenzyme A: Cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 61:1769-1775, 2002
22. ANDERSON RA, JOYCE C, DAVIS M, et al: Identification of a form of acyl-CoA: Cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem 273:26747-26754, 1998
23. OELKERS P, BEHARI A, CROMLEY D, et al: Characterization of two human genes encoding acyl coenzyme A: Cholesterol acyltransferase-related enzymes. J Biol Chem 273:26765-26771, 1998
24. CASES S, NOVAK S, ZHENG YW, et al: ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem 273:26755-26764, 1998
25. CHANG TY, CHANG CCY, CHENG D: Acyl-Coenzyme A: Cholesterol acyltransferase. Annu Rev Biochem 66:613-633, 1997
26. CARR TP, HAMILTON RL, RUDEL LL: ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J Lipid Res 36:25-36, 1995
27. BOCANT MA, KRAUSE BR, ROSEBURY WS, et al: The ACAT inhibitor avasimibe reduces macrophages and matrix metaloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 20:70-79, 2000
28. POST PM, ZOETEWIEJ JP: Bos MH, et al: Acyl-coenzyme A: Cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7α-hydroxylase in cultured rat hepatocytes and in vivo in the rat. Hepatology 30:491-500, 1999
29. GENEST J JR, MARCIL M, DENIS M, et al: High density lipoproteins in health and in disease. J Invest Med 47:31-42, 1999
30. ACTON S, RIGOTTI A, LANDSCHULZ KT, et al: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271:518-520, 1996
31. MULS E, ROSSENEU M, DANEELS R, et al: Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 54:225-237, 1985
32. VAZIRI ND, LIANG K, PARK JS: Acquired lecithin: Cholesterol acyltransferase (LCAT) deficiency in nephrotic syndrome. Am J Physiol 49:F823-F829, 2001
33. FRANCONE OL, GURAKAR A, FIELDING C: Distribution and functions of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem 264:7066-7072, 1989
34. KUIVEVENHOVEN JA, PRITCHARD H, HILL J, et al: The molecular pathology of lecithin: Cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 38:191-205, 1997
35. MURDOCH SJ, BRECKENRIDGE WC: Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis 118:193-212, 1995
36. DAVIES RW, STAPRANS I, HUTCHISON FN, et al: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 86:600-605, 1990
37. LIANG K, VAZIRI ND: Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 130:387-394, 1997
38. LIANG K, VAZIRI ND: Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 51:1933-1937, 1997
39. LIANG K, VAZIRI ND: Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 51:1761-1765, 1997
40. SUN X, JONES H JR, JOLES JA, et al: Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am J Physiol 262:F755-761, 1992
41. KAYSEN CA, HOYE E, JONES H, JR: Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats. Am J Physiol 268:F532-540, 1995
42. SAKU K, MENDOZA SG, LAVER M, et al: High-density lipoprotein apolipoprotein AI and AII turnover in moderate and severe proteinuria. Nephron 50:112-115, 1988
43. OSCHRY Y, EISENBERG S: Rat plasma lipoproteins: Re-evaluation of a lipoprotein system in an animal devoid of cholesteryl ester transfer activity. J Lipid Res 23:1099-1106, 1982
44. DULLAART RP, GANSEVOORT RT, DIKKESCHEI BD, et al: Role of elevated lecithin: Cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney Int 44:91-97, 1993
45. TALL AR: Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 86:379-384, 1990
46. 2 cells. Arterioscler Thromb Vasc Biol 17:2020-2028, 1997
47. LIANG K, VAZIRI ND: Downregulation of hepatic high-density lipoprotein receptor, SR-B1 in nephrotic syndrome. Kidney Int 56:621-626, 1999
48. MARSH JB: Lipoprotein metabolism in experimental nephrosis. J Lipid Res 25:1619-1623, 1984
49. DAVIES RW, STAPRANS I, HUTCHISON FN, et al: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 86:600-605, 1990
50. SHEARER GC, STEVENSON FT, ATKINSON DN, et al: Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 59:179-189, 2001
51. AUWERK J, LEROY P, SCHOONJANS K: Lipoprotein lipase: Recent contributions from molecular biology. Crit Rev Clin Lab Sci 29:243-268, 1992
52. SIMSOLO RB, ONG JM, KERN PA: Characterization of lipoprotein lipase activity, secretion and degradation at different sites of post-translational processing in primary cultures of rat adipocytes. J Lipid Res 33:1777-1784, 1992
53. KASHYAP ML, SRIVASTAVA LS, HYND BA, et al: Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35:29-40, 1980
54. HIRANO T, EBARA T, FURUKAWA S, et al: Mechanism of hypertriglyceridemia in Dahl salt-sensitive rats, an animal model of spontaneous nephrotic syndrome. Metabolism 43:248-256, 1994
55. VAZIRI ND, LIANG K, BARTON CH: Effect of increased afterload on cardiac lipoprotein lipase and VLDL receptor expression. Biochim Biophys Acta 1436:577-584, 1999
56. SATO T, LIANG K, VAZIRI ND: Downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 61:157-162, 2002
57. DICHEK HL, PARROTT C, RONAN R, et al: Functional characterization of a chimeric lipase genetically engineered from human lipoprotein lipase and human hepatic lipase. J Lipid Res 34:1393-1401, 1993
58. STAPRANS I, FELTS JM, COUSER WG: Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats. Metabolism 36:496-501, 1987
59. KRONENBERG F, UTERMANN G, DIEPLINGER H: Lipoprotein(a) in renal disease. Am J Kidney Dis 27:1-25, 1996
60. TAKAHASHI S, KAWARABAYASI Y, NAKAI T, et al: Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 89:9252-9256, 1992
61. JOKINEN EV, LANDSCHULZ KT, WYNE KL, et al: Regulation of the very low density lipoprotein receptor by thyroid hormone in rat skeletal muscle. J Biol Chem 269:26411-26418, 1994
62. WEBB JC, PATEL DD, JONES MD, et al: Characterization and tissue-specific expression of the human very low density lipoprotein (VLDL) receptor mRNA. Hum Mol Gen 3:531-537, 1994
63. TAKAHASHI S, SUZUKI J, KOHNO M, et al: Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 270:15747-15754, 1995
64. FURUKAWA S, HIRANO T, MAMO JC, et al: Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis. Metabolism 39:101-107, 1990
65. LIU AC, LAWN RM: Lipoprotein(a) and atherogenesis. Trend Cardiovasc Med 4:40-44, 1994
66. MCLEAN JW, TOMLINSON JE, KUANG WJ, et al: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137, 1987
67. LACKNER C, COHEN JC, HOBBS HH: Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 2:933-940, 1993
68. FAUCHER C, DOUCET C, BAUMELOU A, et al: Elevated lipoprotein(a) levels in primary nephrotic syndrome. Am J Kidney Dis 22:808-813, 1993
69. KARADI I, ROMICS L, PALOS G, et al: Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 35:2121-2123, 1989
70. STENVINKEL P, BERGLUND L, ERICSSON S, et al: Low density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. Eur J Clin Invest 27:169-177, 1997
71. DE SAIN-VAN DER VELDEN MG, REIJINGOULD DJ, KAYSEN GA, et al: Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 9:1474-1481, 1998
72. VAZIRI ND, PAULE P, TOOHEY J, et al: Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 144:1802-1803, 1984
73. 2-antiplasmin, in plasma and urine of patients with nephrosis. J Lab Clin Med 117:152-156, 1991
74. VAZIRI ND: Nephrotic syndrome and coagulation and fibrinolytic abnormalities. Am J Nephrol 3:1-6, 1983
75. VAZIRI ND, BARTON CH: Renal vein thrombosis, in Current Therapy in Nephrology and Hypertension (4th ed), edited by GLASSOCK R, Philadelphia, Mosby, 1998, pp 269-274
76. VAZIRI ND: Endocrinological consequences of nephrotic syndrome. Am J Nephrol 13:360-364, 1993